Larvol Delta - Influence-of-newly-initiated-biologic-therapy-on-the-dose-of-ICS-therapy--Data-from-the-German-Asthma-Net

Cinqair (reslizumab) - Merck (MSD), UCB, Teva

Xolair (omalizumab) - Roche, Novartis

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

Nucala (mepolizumab) - GSK

Fasenra (benralizumab) - AstraZeneca

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42777915

; Andreas Renner; Christian Schulz; Christian Taube; Christina Bal; Christoph Krall; Dirk Skowasch; Eckard Hamelmann; Katrin Milger; Marco Idzko; Margret Jandl; Olaf Schmidt; Rainer Ehmann; Roland Buhl; Slagjana Stoshikj; Stephanie Korn

Sep 24, 2026